Loncar China BioPharma ETF (CHNA)
| Assets | $6.34M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 300,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 29, 2021 |
| Payout Ratio | n/a |
| 1-Year Return | -6.32% |
| Volume | 3,663 |
| Open | 21.25 |
| Previous Close | 21.61 |
| Day's Range | 19.77 - 21.54 |
| 52-Week Low | 13.35 |
| 52-Week High | 22.85 |
| Beta | 0.68 |
| Holdings | 64 |
| Inception Date | Aug 14, 2018 |
About CHNA
The Loncar China BioPharma ETF (CHNA) is an exchange-traded fund that is based on the Loncar China BioPharma index. The fund tracks a tier-weighted index of companies directly involved in the growth of Chinas pharmaceutical and biotech industry. CHNA was launched on Aug 14, 2018 and is managed by Loncar.
Top 10 Holdings
26.55% of assets| Name | Symbol | Weight |
|---|---|---|
| Akeso Inc Ordinary Shares | 9926.HK | 3.53% |
| Keymed Biosciences Inc | 2162.HK | 3.23% |
| BeiGene, Ltd. | BGNE | 2.97% |
| Hangzhou Tigermed Consulting Co Ltd Class H | 3347.HK | 2.83% |
| 3SBio Inc Shs Unitary 144A/Reg S | 1530.HK | 2.50% |
| Luye Pharma Group Ltd | 2186.HK | 2.42% |
| Wuxi AppTec Co Ltd | 2359.HK | 2.36% |
| CSPC Pharmaceutical Group Ltd | 1093.HK | 2.26% |
| HUTCHMED (China) Limited | HCM | 2.23% |
| Sino Biopharmaceutical Ltd | 1177.HK | 2.22% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2021 | $3.03143 | Dec 31, 2021 |
| Dec 30, 2020 | $0.15462 | Jan 4, 2021 |
| Dec 23, 2019 | $0.04025 | Dec 26, 2019 |
News
China ETFs Lead the Way in This Week's Top Performing ETFs
This week's top-performing ETFs include five China-focused strategies, a far cry from the panic that China would be uninvestable following the Fall's Chinese Communist Party Congress. Led by the top E...
4 Best Areas of Q4 Up At Least 20% & Their Top ETFs
The fourth quarter of 2022 is just about to wrap up. The broader market has posted mixed performance during this time frame.
5 Best-Performing ETFs of Last Week
Wall Street was downbeat last week on rising rate fears and recessionary concerns.
4 China ETFs Beating S&P 500 in its Worst Week Since 2008
Check these China ETFs that beat the S&P 500 in the past week, which was U.S. equities?
Best Pharmaceutical ETFs for Q1 2020
The best pharmaceutical ETFs for Q1 2020 are KURE, CHIH, and CHNA.
Why These Chinese Sector ETFs Are Crushing S&P 500 in 2019
Policy easing in the Chinese economy, cooling trade tensions with the United States and Beijing's efforts for more urbanization have boosted these sector ETFs in 2019.